GlassScriptPhysician profile
Sidney M Broder
NPI 1851465025
$1,701.69
in general payments reported to CMS, 2019-2025
20 companies · $860 in 2025
The $860 reported for 2025 was more than what 84% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
See the full distribution for Neuromusculoskeletal Medicine & OMM
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $37.71 · 2021: $33.51 · 2022: $43.06 · 2023: $173 · 2024: $171 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.25 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $687.18 | 2019-2025 | Tysabri, Vumerity |
| Abbvie INC. | $439.18 | 2021-2025 | Botox |
| Aucta Pharmaceuticals, INC. | $118.11 | 2025 | Motpoly Xr |
| Novartis Pharmaceuticals Corporation | $86.23 | 2021-2025 | |
| Eisai INC. | $53.42 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $39.97 | 2025 | Austedo Xr |
| Lilly USA, LLC | $33.14 | 2019-2024 | Kisunla |
| Cycle Pharmaceuticals INC | $29.00 | 2025 | Tascenso Odt, Bafiertam |
| Livanova USA, INC. | $27.12 | 2025 | Vns Therapy |
| Tanabe Pharma America, INC. | $25.97 | 2025 | Radicava |
| Supernus Pharmaceuticals, INC. | $24.28 | 2019-2020 | |
| Emd Serono, INC. | $22.01 | 2019 | |
| Ucb, INC. | $16.43 | 2025 | Rystiggo |
| Genzyme Corporation | $16.35 | 2025 | |
| Genentech USA, INC. | $15.28 | 2025 | Ocrevus Zunovo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $14.13 | 2025 | Valtoco |
| Axsome Therapeutics, INC. | $13.86 | 2025 | Symbravo |
| Vanda Pharmaceuticals INC. | $13.73 | 2025 | Ponvory |
| Biohaven Pharmaceutical Holding Company LTD. | $13.64 | 2022 | |
| Amgen INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Broder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.